Activity-Structure Study on the Peptide Fraction of AG2: a Potent In Vitro Transfection Agent
Gemini-based amphiphiles are candidates for biomedical applications. In fact, most of the gemini compounds described in the literature have been prepared to be used as new synthetic vectors in gene transfection. Our group carried out an activity-structure study starting from the structure of the gemini [AG2-C18/]2, which is an effective in vitro transfection reagent. We synthesized a series of novel amphiphilic amino acid derivatives of low molecular weight, named AGn-Cm (N), in which the same apolar region (m) of oleic or palmitic acid was maintained and the peptide region was modified by amino acid insertions, deletions, and substitutions. We also determined the transfection efficiency, critical micelle concentration, particle size, and ζ-potential for these derivatives. Amphiphiles AG10-C16 and AG10-C18 were more active at a lower N/P ratio than AG2-C18. These amphiphiles showed no activity when lysine was replaced by ornithine, and the activity of all derivatives increased when there were more ornithine residues and a W/O = 1 ratio in the peptide region. It can be said that for AG10-C16, these two structural requirements on the amino acid portion predominated over the type of aliphatic chain used.
KeywordsAmphiphile N-Acylated Cysteine Gemini Ornithine Transfection
This work was supported by grants from CAI+D 2016, Seed Capital, and the University Policies System (SPU) of the Universidad Nacional del Litoral (U.N.L).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
- 3.Degiorgio, V., & Conti, M. (1985). Physics of amphiphiles, micelles, vesicles, and microemulsions (pp. 665–684). North-Holland Publishing Company.Google Scholar
- 9.Damen, M., Aarbiou, J., van Dongen, S. F., Buijs-Offerman, R. M., Spijkers, P. P., van den Heuvel, M., Kvashnina, K., Nolte, R. J., Scholte, B. J., & Feiters, M. C. (2010). Delivery of DNA and siRNAby novel gemini-like amphiphilic peptides. Official Journal of the Controlled Release Society, 145(1), 33–39.CrossRefGoogle Scholar
- 10.Kelleher, T.J., Lai, J.J., DeCourcey, J.P., Lynch, P., Zenoni, M. & Tagliani, A. (2000). High purity lipopeptides, lipopeptide micelles and processes for preparing same. US6696412B1.Google Scholar
- 11.Kuhner, C., & Romesser, J. (2001). Compositions and methods of use of peptides in combination with biocides and/or germicides. WO2003091276A3.Google Scholar
- 12.Adami, R.C., Houston, M. E. & Johns, R.E. (2009). Lipopeptides for delivery of nucleic acids. WO 2009046220 A3.Google Scholar
- 13.Laverty, G., Gorman, S. P., & Gilmore, B. F. (2012). Antimicrobial peptide incorporated poly (2-hydroxyethyl methacrylate) hydrogels for the prevention of Staphylococcus epidermidisassociated biomaterial infections. Journal of Biomedical Materials Research Part A, 100(7), 1803–1814.CrossRefPubMedGoogle Scholar
- 14.Kamysz, E., Sikorska, E., Dawgul, M., Tyszkowski, R., & Kamysz, W. (2015). Influence of dimerization of lipopeptide Laur-Orn-Orn-Cys–NH2 and an N-terminal peptide of human lactoferricin on biological activity. International Journal of Peptide Research and Therapeutics, 21(1), 39–46.CrossRefPubMedGoogle Scholar
- 15.Kuliopulos, A. (2012). Polypeptide and lipophilic moiety conjugate compositions, formulations, and uses related thereof. CA2923595A1.Google Scholar
- 16.Shubh, S., Der Ploeg, L., & Herderson, B. (2013). Pharmaceutical compositions. WO2014144842A2.Google Scholar
- 17.Mograbi, J., Atlas, D. & Keynan, S. (2017). Antioxidant, anti-inflammatory, anti-radiation, metal chelating compounds and uses thereof. EP 3121189 A1.Google Scholar
- 19.Kruse, T., Sensfuss, U., & Clausen, T.R. (2017). Novel peptides and peptide derivatives and uses thereof. WO2017005765.Google Scholar
- 20.Chang, W. C. (2004). Fmoc solid phase peptide synthesis: a practical approach. Oxford: Oxford University Press.Google Scholar
- 21.Campeau, E., Ruhl, V. E., Rodier, F., Smith, C. L., Rahmberg, B. L., Fuss, J. O., Campisi, J., Yaswen, P., Cooper, P. K., & Kaufman, P. D. (2009). A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One, 4(8), e6529. https://doi.org/10.1371/journal.pone.0006529.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Lobo, B. A., Rogers, S. A., Wiethoff, C. M., Choosakoonkriang, S., Bogdanowich-Knipp, S., & Middaugh, C. R. (2001). Characterization of cationic vector-based gene delivery vehicles using isothermal titration and differential scanning calorimetry. Methods in Molecular Medicine, 65, 319–348.PubMedGoogle Scholar
- 28.Fielden, M., Perrin, C., Kremer, A., Bergsma, M., Stuart, M. C., Camilleri, P., & Engberts, J. (2001). Sugar-based tertiary amino gemini surfactants with a vesicle-tomicelle transition in the endosomal pH range mediate efficient transfection in vitro. European Journal of Biochemistry, 268(5), 1269–1279.CrossRefPubMedGoogle Scholar
- 32.Koloskova, O. O., Nikonova, A. A., Budanova, U. A., Shilovskiy, I. P., Kofiadi, I. A., Ivanov, A. V., Smirnova, O. A., Zverev, V. V., Sebaykin, Y. L., Andreev, S. M., & Khaitov, M. R. (2016). Synthesis and valuation of novel Lipopeptide as a vehicle for efficient gene delivery and gene silencing. European Journal of Pharmaceutics and Biopharmaceutics, 102, 159–167.CrossRefPubMedGoogle Scholar
- 33.Almutary, A. and Sanderson, B.J. S. (2016). “The MTT and crystal violet assays: potential confounders in nanoparticle toxicity testing”. International Journal of Toxicology, 1–9. Google Scholar